Results from Astellas ' Pivotal Phase 3 SKYLIGHT 1 ™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet

TOKYO, March 13, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced The Lancet published detailed results from the pivotal Phase 3 SKYLIGHT 1™ study of fezolinetant, an...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials